RecruitingEarly Phase 1NCT07067905
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
Sponsor
Chinese PLA General Hospital
Enrollment
15 participants
Start Date
Jun 27, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Safety, tolerability, and biodistribution characteristics of 68Ga-XT771 will also be assessed.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- \. signed the informed consent 2. ≥18 years old 3. Patients with glioblastoma or clear cell renal cell carcinoma
Exclusion Criteria1
- \. Known allergy to components of the investigational drug or its analogues 2. suspected to have a certain disease or condition that is not suitable for the study drug 3. Known pregnant or lactating women
Interventions
DRUG68Ga-XT771
68Ga-XT771 is injected intravenously with a dose of 4-8 mCi
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07067905